1.86
price down icon5.84%   -0.11
after-market Handel nachbörslich: 1.86
loading

Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten

pulisher
01:36 AM

Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World

01:36 AM
pulisher
Mar 10, 2025

Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN

Mar 07, 2025
pulisher
Feb 28, 2025

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St

Feb 28, 2025
pulisher
Feb 28, 2025

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK

Feb 28, 2025
pulisher
Feb 28, 2025

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Tango Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Can Tango's Cancer Breakthroughs in Pancreatic and Lung Cancer Outweigh Its Growing Losses? - StockTitan

Feb 27, 2025
pulisher
Feb 23, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Feb 23, 2025
pulisher
Feb 23, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter

Feb 23, 2025
pulisher
Feb 20, 2025

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

Can Tango's Synthetic Lethality Approach Transform Cancer Treatment? Key Conferences to Watch - StockTitan

Feb 20, 2025
pulisher
Feb 18, 2025

Tango Therapeutics executive sells shares worth $43,865 - MSN

Feb 18, 2025
pulisher
Feb 15, 2025

Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Declines By 22.5% - MarketBeat

Feb 15, 2025
pulisher
Feb 11, 2025

Analysts Offer Predictions for TNGX Q3 Earnings - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Q1 Earnings Forecast for TNGX Issued By Leerink Partnrs - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Q3 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 Shares - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman Sells 4,284 Shares - MarketBeat

Feb 10, 2025
pulisher
Feb 09, 2025

Adam Crystal Sells 7,432 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Tango Therapeutics Inc (NASDAQ: TNGX): Can A Stock Be -1.94% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN

Feb 08, 2025
pulisher
Feb 08, 2025

One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Yahoo Finance

Feb 08, 2025
pulisher
Feb 08, 2025

What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings? - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN

Feb 07, 2025
pulisher
Feb 07, 2025

Tango Therapeutics CFO Beckman sells $25,281 in stock By Investing.com - Investing.com South Africa

Feb 07, 2025
pulisher
Feb 07, 2025

Tango Therapeutics CEO Barbara Weber sells $57,710 in stock By Investing.com - Investing.com Australia

Feb 07, 2025
pulisher
Feb 07, 2025

Tango Therapeutics executive sells shares worth $43,865 By Investing.com - Investing.com Australia

Feb 07, 2025
pulisher
Feb 06, 2025

Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Is Tango Therapeutics Inc (TNGX) worth investing in despite its overvalued state? - US Post News

Feb 06, 2025
pulisher
Feb 06, 2025

TNGX’s 2023 Market Dance: Up 8.41% – Time to Invest? - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

Exclusive BAC Article: Tango Therapeutics; 2nd Half Of 2024 MTAP-Deletion Tumor Data TNG-908/TNG-462, TNG-260 Phase 1/2 Trial Advancement And Catalysts (NASDAQ:TNGX) - Seeking Alpha

Feb 05, 2025
pulisher
Feb 05, 2025

TNGX (Tango Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Tango Therapeutics Inc’s Market Journey: Closing Strong at 3.04, Up 4.47 - The Dwinnex

Feb 05, 2025
pulisher
Feb 01, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $13.14 Average Price Target from Analysts - MarketBeat

Feb 01, 2025
pulisher
Jan 30, 2025

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - The Manila Times

Jan 30, 2025
pulisher
Jan 30, 2025

Precision Cancer Medicine Pioneer Tango Therapeutics Takes Center Stage at Elite Biotech Conference - StockTitan

Jan 30, 2025
$305.39
price down icon 0.49%
$34.30
price down icon 2.13%
$32.68
price down icon 0.56%
$19.19
price down icon 3.69%
$97.47
price down icon 2.86%
biotechnology ONC
$254.51
price up icon 1.87%
Kapitalisierung:     |  Volumen (24h):